M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss

The current frontline symptomatic treatment for Alzheimer’s disease (AD) is whole-body upregulation of cholinergic transmission via inhibition of acetylcholinesterase. This approach leads to profound dose-related adverse effects. An alternative strategy is to selectively target muscarinic acetylchol...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Bradley, Sophie J., Bourgognon, Julie-Myrtille, Sanger, Helen E., Verity, Nicholas, Mogg, Adrian J., White, David J., Butcher, Adrian J., Moreno, Julie A., Molloy, Colin, Macedo-Hatch, Timothy, Edwards, Jennifer M., Wess, Jurgen, Pawlak, Robert, Read, David J., Sexton, Patrick M., Broad, Lisa M., Steinert, Joern R., Mallucci, Giovanna R., Christopoulos, Arthur, Felder, Christian C., Tobin, Andrew B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5272187/
https://ncbi.nlm.nih.gov/pubmed/27991860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87526
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi